University Hospital Heidelberg

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Coreline Soft Showcases Deep Learning AI Imaging Solutions ‘AVIEW’ at ECR 2024

Retrieved on: 
Wednesday, February 14, 2024
Technology, Medical Devices, Hospitals, Audio, Video, Radiology, University, Health, Education, Oncology, Artificial Intelligence, ILSP, Hospital, European Congress of Radiology, ACS, University Hospital Heidelberg, Exhibition, National Cancer Institute, Chronic obstructive pulmonary disease, ECR, Imagen, Idna, Lung cancer, Congress, Diagnosis, Medical device

Coreline Soft , a pioneer in medical artificial intelligence (AI) imaging, unveils cutting-edge AI medical imaging solutions at the ECR 2024 (European Congress of Radiology), establishing a new standard for healthcare across Europe.

Key Points: 
  • Coreline Soft , a pioneer in medical artificial intelligence (AI) imaging, unveils cutting-edge AI medical imaging solutions at the ECR 2024 (European Congress of Radiology), establishing a new standard for healthcare across Europe.
  • Coreline Soft is set to make a mark at the ECR 2024 by presenting its AVIEW product line.
  • Coreline Soft has been actively expanding its presence in Europe, securing projects such as the multinational lung cancer screening initiative (iDNA) involving five European countries.
  • Coreline Soft continues to strengthen its global presence, offering innovative AI solutions to advance healthcare practices in Europe and beyond.

New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe

Retrieved on: 
Wednesday, January 31, 2024
Breast, Regenerative medicine, 3D, Pectus excavatum, Patient, ISO, Trauma, University Hospital Heidelberg, IIT, Clinic, Learning, Medtech, Professor, Medical device

In 2023, BellaSeno had received market authorization for its custom-made, resorbable bone and pectus excavatum scaffolds in Europe.

Key Points: 
  • In 2023, BellaSeno had received market authorization for its custom-made, resorbable bone and pectus excavatum scaffolds in Europe.
  • The clinical pectus excavatum trial in Italy will enroll a total of 10 patients, with 4 individuals having undergone surgery already.
  • While initial clinical use cases in Australia demonstrated promisingoutcomes last year, this is the first time that a fully resorbable sternal prosthesis is being used in Europe.
  • "We are excited that several leading European university hospitals have decided to evaluate our scaffolds in independent clinical trials.

VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, QT interval, Cardiac arrest, National Center for Health Research, Acute myeloid leukemia, ECG, European Commission, Hypokalemia, Committee, European Directive on Traditional Herbal Medicinal Products, Febrile neutropenia, MD, Professor, News, University Hospital Heidelberg, EC, Maintenance, Pneumonia, Arrhythmia, Ventricular fibrillation, ALAN, Civil service commission, Daiichi Sankyo, Risk, TSE, HR, Leukemia, FLT3, Committee for Medicinal Products for Human Use, Safety, German Cancer Research Center, European, Patient, Death, Neutropenia, AML, Nursing, Pharmaceutical industry, EU, Lancet

VANFLYTA is the first FLT3 inhibitor approved in the EU specifically for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which represents about 25 to 30% of all new AML cases.1,2

Key Points: 
  • VANFLYTA is the first FLT3 inhibitor approved in the EU specifically for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which represents about 25 to 30% of all new AML cases.1,2
    The authorization by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on the results of the QuANTUM-First trial, which were published in The Lancet .
  • The most common grade 3 or 4 treatment emergent adverse events (occurring in ≥ 10% of patients) were febrile neutropenia (43%), hypokalemia (19%), neutropenia (18%) and pneumonia (11%).
  • QTcF > 500 ms occurred in 2.3% of patients receiving VANFLYTA and 0.8% of patients discontinued VANFLYTA due to QT prolongation.
  • Two (0.8%) patients receiving VANFLYTA experienced cardiac arrest with recorded ventricular fibrillation on ECG (one with fatal outcome), both in the setting of severe hypokalemia.

EQS-News: International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Retrieved on: 
Wednesday, September 6, 2023
Royal Surrey County Hospital, Hospice and palliative medicine, University, Consultant, E pluribus unum, RRT, Critical Care (journal), Overalls, Renal replacement therapy, Biomarker, AKI, Intensive care medicine, Acute kidney injury, CRRT, Professor, University Hospital Heidelberg, Patient, School, RICH, Mortality, University of Surrey, Intensive care unit, Health, Southern Illinois University School of Medicine, Pharmaceutical industry, Medical imaging, Nursing

Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.

Key Points: 
  • Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.
  • RRT, a common practice in Intensive Care Units (ICUs), has long relied on clinical observations for stop decisions.
  • However, the lack of a dependable biomarker poses challenges in accurately assessing when to discontinue RRT.
  • Considering this, leading experts from the field have discussed in a recent advisory board the importance of identifying the right tools to improve the outcomes in AKI.

Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts

Retrieved on: 
Tuesday, August 29, 2023
GE HealthCare, Therapy, Reder, Cone Health Women's Hospital, Cancer, Benveniste affair, Research, Harvard University, Harvard Medical School, Alpenglow, University Hospital Heidelberg, Patient, Cardiology, Diagnosis, Entrepreneurship, Hospital, Pharmacology, MPH, Summit, Laboratory, Medical imaging, Brigham, MD

CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.
  • The inaugural Summit stands to become the premier event focused on the emerging field of 3D Spatial Biology.
  • The event will encompass essential tools, data processing, and data analytics capabilities necessary for extracting meaningful biological insights to support scientific discovery and the advancement of life-saving therapeutics.
  • The 3D Spatial Summit features an impressive speaker list comprising key opinion leaders from academia and industry to offer varied perspectives on the burgeoning application of 3D spatial biology in answering pivotal disease-related questions.

iotaSciences Appoints Dr. Michael Lutz as New Chief Executive Officer

Retrieved on: 
Thursday, August 3, 2023
Health, Genetics, Health Technology, Research, Science, Biotechnology, Acceleration, University, Chairperson, Senior, Berlin-Buch station, ETH Zurich, University Hospital Heidelberg, Biology, Management, Fine chemical

iotaSciences, the Oxford-based leader in the rapidly growing field of single-cell handling solutions announced today the appointment of Dr. Michael Lutz as CEO and Director for Iota Sciences Ltd.

Key Points: 
  • iotaSciences, the Oxford-based leader in the rapidly growing field of single-cell handling solutions announced today the appointment of Dr. Michael Lutz as CEO and Director for Iota Sciences Ltd.
  • Prior to joining iotaSciences, Dr. Lutz was CEO of HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases.
  • Dr. Alexander Feuerborn, with a Ph.D in biology from the University of Heidelberg, Germany, and co-Founder of iotaSciences will assume the role of Chief Product Officer and focus on advanced product development and application sciences.
  • Henry Walker will act as Chief Technical Officer focusing on all product manufacturing aspects.

TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing

Retrieved on: 
Thursday, July 6, 2023
MIC, National Transportation Safety Board, Frontiers, HLA, CSO, Immune tolerance, Clinical trial, Antibody, DSA, Fungal infection, Transplant, Incidence, EUR, Patient, Immune system, Series, Autoimmune disease, Methylprednisolone, Kidney transplantation, University Hospital Heidelberg, Leukapheresis, BMJ Open, Autoimmunity, Dentistry, Medical device, Immunology

Furthermore, the company is publishing 5-year follow-up data of a Phase I trial of its MIC-Lx cell therapy.

Key Points: 
  • Furthermore, the company is publishing 5-year follow-up data of a Phase I trial of its MIC-Lx cell therapy.
  • Our preclinical studies also demonstrate great potential in autoimmune disease"
    On the back of these promising results, TolerogenixX also reported a EUR 7 million second closing of its Series A financing round now totaling EUR 11.6 million.
  • "We are very pleased that we were able to add EUR 7 million to our Series A financing round," Schaier said.
  • "In the current financing environment, this is a further validation of our approach, enabling us to successfully complete our Phase II program."

AKTIS ONCOLOGY EXPANDS SCIENTIFIC ADVISORY BOARD TO ADVANCE PIPELINE OF TARGETED ALPHA RADIOPHARMACEUTICALS

Retrieved on: 
Thursday, June 15, 2023
SAB, Endocrinology, University, United States Air Force Scientific Advisory Board, DRS, Radiopharmaceutical, Doctor of Philosophy, McKinsey & Company, Novartis, AAA, University Hospital Heidelberg, Education minister, R, Research, Advanced Accelerator Applications, Pharmaceutical industry, Ǵermo, Olympiaki Akti, MD

BOSTON, June 15, 2023 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the appointment of Germo Gericke, MD, to its Scientific Advisory Board (SAB). Dr. Gericke joins Drs. Ken Herrmann (SAB Chair), Patrick Baeuerle, Erik Chelius, Johannes Czernin, Gary Glick, and Dane Wittrup on the Aktis SAB in advising the company on scientific and clinical development matters.

Key Points: 
  • BOSTON, June 15, 2023 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the appointment of Germo Gericke, MD, to its Scientific Advisory Board (SAB).
  • Dr. Gericke is a clinical development expert with a special focus on oncology and radiopharmaceuticals.
  • "I'm delighted to welcome Germo to Aktis' SAB," said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology.
  • "Germo's extensive clinical leadership experience and radiopharmaceutical development expertise will provide valuable insights to Aktis as we advance our pipeline of novel radiopharmaceuticals toward the clinic."